# US 11,439,684 B2 · Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,684 B2
- Document ID: US11439684B2
- Status: Granted
- Kind: B2
- Application number: 16/486,863
- Filed: 2018-02-20
- Published: 2020-07-23
- Granted: 2022-09-13
- Earliest claimed: 2017-02-21
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Luis F. Porrata; Svetomir N. Markovic
- Web page: https://patentgrep.com/patent/US11439684B2

## CPC

- A61K 38/2086: {IL-13 to IL-16}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/20: Interleukins [IL]
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are materials and methods for assessing ratios of lymphocyte to monocytes in cancer patients and, based on the ratios, treating the cancer patients with an immunotherapeutic.

## Claims

### Claim 1

A method for treating a cancer patient, said method comprising administering a pharmaceutical composition comprising an immunotherapeutic agent to a cancer patient identified as having a biological sample with a natural killer (NK):CD14+HLA-DRDIM ratio less than 0.29, wherein the cancer is non-Hodgkin's lymphoma, and wherein the immunotherapeutic agent is IL-15, IL-21, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient was identified based on a NK:CD14+HLA-DRDIM ratio determined at initial diagnosis of the cancer or prior to treatment.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient has received an autologous peripheral hematopoietic stem cell transplantation (APBHSCT), and wherein the patient was identified based on a NK:CD14+HLA-DRDIM ratio calculated using absolute NK cell count and absolute CD14+HLA-DRDDIM count in a blood sample obtained from the patient after the APBHSCT.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient was treated with chemotherapy, and wherein the patient was identified based on a NK:CD14+HLA-DRDIM ratio calculated using absolute NK cell count and absolute CD14+HLA-DRDDIM count within a blood sample obtained from the patient after the chemotherapy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient was identified as having a NK:CD14+HLA-DRDIM ratio less than 0.25.